Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
一线治疗
第一行
奥比努图库单抗
作者
William G. Wierda,John N. Allan,Tanya Siddiqi,Thomas J. Kipps,Stephen Opat,Alessandra Tedeschi,Xavier C. Badoux,Bryone J. Kuss,Sharon Jackson,Carol Moreno,Ryan Jacobs,John M. Pagel,Ian W. Flinn,Yvonne Pak,Cathy Zhou,Edith Szafer-Glusman,Joi Ninomoto,James P. Dean,Danelle F. James,Paolo Ghia,Constantine S. Tam
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology] 日期:2021-10-07卷期号:39 (34): 3853-3865被引量:5
PURPOSECAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax t...